<DOC>
	<DOCNO>NCT01208012</DOCNO>
	<brief_summary>The trial phase IV clinical trial investigate impact Liraglutide endothelial function microvascular blood flow 44 patient type 2 diabetes mellitus age 30-65 HbA1c range ≥ 5.5 % ≤ 7.0 % . The patient randomize two study arm , one arm treat Metformin monotherapy , second arm treat Metformin Liraglutide increase dose ( 0.6 mg/day 1.8 mg/day . )</brief_summary>
	<brief_title>Impact Liraglutide Endothelial Function Microvascular Blood Flow Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Type 2 Diabetes Mellitus ( DM ) associate increase cardiovascular risk majority type 2 diabetic patient die due vascular complication Diabetes Mellitus . In type 2 diabetic patient , early marker biogenesis atherosclerosis cardiovascular disease occurrence endothelial dysfunction subsequent deterioration micro- macrovascular blood flow tissue supply . Also several mechanistic pathway link Diabetes Mellitus endothelial dysfunction cardiovascular complication postulate . Recent study aim investigate vasoprotective effect strict glycaemic control use conventional treatment algorithm fail reduce cardiovascular risk patient Diabetes Mellitus type 2 . Numerous pharmacological drug available reduce blood glucose level type 2 diabetic patient . Beside comparable glucose lower efficacy , evolve limit even adverse effect vascular function cardiovascular risk . Therefore , ideally new treatment Diabetes Mellitus type 2 provide reduce blood glucose value . Future treatment type 2 Diabetes Mellitus judge potency affect cardiovascular risk profile patient Diabetes Mellitus type 2 . Liraglutide Glucagon-like peptide-1 ( GLP-1 ) analogue show effective treatment type 2 Diabetes Mellitus . Liraglutide show improve blood glucose level stimulate insulin secretion β cell , also improve conversion intact proinsulin insulin C-peptide granula β cell . While rodent , GLP-1 analogue show increase β cell regeneration inhibitory effect β cell apoptosis , effect GLP-1 analogue β cell mass humans less clear . Beyond effect β cell , Liraglutide GLP1 analogues show suppress glucagon release α cell evolve supportive effect weight reduction central probably peripheral effect . Beside effect GLP-1-analogues β cell physiology glucose metabolism , recent study suggest several pleiotrophic effect GLP-1 treatment go beyond glycaemic control . Receptors GLP-1 locate myocardial endothelial cell , GLP-1 supplementation find improve myocardial endothelial function diabetic non-diabetic subject . In endothelial cell , isolated human coronary artery , GLP-1 rapidly activate endothelial nitric oxide synthase ( eNOS ) stimulate nitric oxide ( NO ) production , promote cell proliferation inhibits glucolipoapoptosis . In addition , transform vascular endothelial cell , GLP-1 protect endothelial dysfunction incur tumor necrosis factor-α ( TNF-α ) modulation expression vascular adhesion molecule plasminogen activator inhibitor-1 ( PAI-1 ) . Chronic administration GLP-1 analogue associate significant reduction blood pressure . Therefore seem conceivable , patient Diabetes Mellitus type 2 , treatment GLP-1 analog Liraglutide might improve cardiovascular risk profile beyond glucose control stimulate endothelial NO release improve endothelial function . The goal study investigate vascular endothelial effect add Liraglutide treatment type 2 diabetic patient previously treat Metformin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Diabetes Mellitus type 2 2 . HbA1c ≥ 5.5 % ≤ 7.0 % 3 . Treatment Metformin ( daily dose 500 3000 mg monotherapy , past 3 month ) 4 . Age 30 65 year 1 . Pretreatment PPAR gamma agonist DPP IV inhibitor GLP1 analogue within last three month 2 . History type 1 Diabetes Mellitus 3 . No full legal mental physical ability give inform consent 4 . Uncontrolled hypertension ( systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 90 mmHg ) 5 . Anamnestic acute chronic infection 6 . Inflammatory bowel disease and/or diabetic gastroparesis 7 . Anamnestic history epilepsy 8 . Anamnestic history hypersensitivity study drug drug similar chemical structure 9 . History severe multiple allergy 10 . Treatment investigational drug within 3 month trial entry 11 . Progressive fatal disease 12 . History drug alcohol abuse past 2 year 13 . Liver disease ASAT ALAT 3 time upper normal limit 14 . Serum potassium &gt; 5.5 mmol/L 15 . Moderate Severe Kidney disease GFR ≤ 60 ml/min 16 . Pregnancy breast feed 17 . Sexually active woman childbearing potential practicing highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal IUDs , sexual abstinence vasectomise partner 18 . Have one unexplained episode severe hypoglycaemia ( define require assistance another person due disable hypoglycaemia ) within 6 month prior screen visit 19 . History dehydration , diabetic precoma , diabetic ketoacidosis diabetic gastroparesis 20 . Acute ( within previous 2 day ) schedule investigation iodine contain radiopaque material 21 . Acute myocardial infarction , open heart surgery cerebral event ( stroke/TIA ) within previous 6 month 22 . Anamnestic uncontrolled unstable angina pectoris , pericarditis , myocarditis , endocarditis , haemodynamic relevant aortic stenosis , aortic aneurysma heart insufficiency NYHA III IV 23 . Anamnestic recent pulmonary embolism pulmonary insufficiency 24 . Smoking within last 6 month ( &gt; 1 cigarette/day ) 25 . Planned change antidiabetic , lipid lower blood pressure medication</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Diabetes Mellitus treatment Metformin</keyword>
</DOC>